Cullinan Therapeutics to Present First Data for CLN-619, a

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...

Related Keywords

Virginia ,United States ,Chad ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Jeffrey Jones ,Alexander Spira ,Jeff Jones ,Rose Weldon ,American Society Of Clinical Oncology ,Exchange Commission ,Virginia Cancer Specialists Research Institute ,Development Plan ,Linkedin ,Cullinan Therapeutics Inc ,Nasdaq ,Clinical Oncology ,Annual Meeting ,Key Clinical Results ,Combination Arm ,Combination Cohorts ,Updated Key Clinical Results ,Chief Medical Officer ,Olive Investor ,Investor Event ,Cullinan Therapeutics ,Chad Messer ,Private Securities Litigation Reform Act ,Annual Report ,